Peter Ellmark retweeted
In honor of #InternationalWomensDay, we recognize the following remarkable women who lead important #JITC sections as editors. Thank you! 👏
Dr. Sandra Demaria @WeillCornell
Dr. @MarcelaMaus (MassGen)
Dr. Claudia Palena @theNCI
Dr. Alexandra Snyder @generate_biomed
Peter Ellmark retweeted
Congratulations to #JITC Section Editor Dr. Cornelis "Kees" Melief of @UniLeidenNews for being recognized as this year's Pedro J. Romero Service to JITC Award recipient! Thank you for all of your leadership and for sharing your vision with the journal!
Peter Ellmark retweeted
Prof. Leisha A. Emens MD PHD, incoming President of SITC “The Society is working to put itself out of business” curing #cancer/new VP, Dr James L. Gulley MD PHD - SITC “Family, Friends, Country” THE SOCIETY IS IN GREAT HANDS! @gulleyj1 @theNCI @FDAOncology @sitcancer #SITC2022
Peter Ellmark retweeted
Congratulations to this year's #JITC Best Paper Award recipients - the first authors of top original research papers from the past year! Read the papers using the QR codes and hear more about them during Session 207 in hall 205ABC! #SITC22 @McAuliffe_James @ShrutiGkidney
Peter Ellmark retweeted
The Steven A. Rosenberg Scholar Award Recipient is Dr. @emilykeungMD @MDAndersonNews @JenWargoMD !! #SITC2022 #SITC22 @sitcancer
Peter Ellmark retweeted
New #JITC article: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies bit.ly/3DuOa9R @EllmarkPeter
Peter Ellmark retweeted
Alligator Bioscience starts clinical phase I study with ATOR-1015 bit.se/q8FblR
Peter Ellmark retweeted
Scrip interviewed CEO Per Norlén last week at BIO-Europe on the company's business development strategies and development triggers. youtube.com/watch?v=80yhRt_c… … …
#bioeurope #immunooncology #arevolutionforlife
Peter Ellmark retweeted
Busy days for Alligator at @sitcancer in Washington DC. The three preclinical projects ATOR-1015, ATOR-1017 and ALG.APV-527 all to be showcased at the conference. #immunooncology #arevolutionforlife sitcancer.org/2018/home
Peter Ellmark retweeted
@AlligatorBio Vice President Discovery Peter Ellmark giving a talk in Copenhagen on the topic "Public Private Partnership in Immuno-Oncology" #IOCPH18 #arevolutionforlife
Peter Ellmark retweeted
CEO Per Norlén now on stage @VatorSecurities Unicorn Summit @MediconVillage telling the exciting Alligator story to a high level investor audience. #immunooncology #nextgenerationctla4 #arevolutionforlife
Peter Ellmark retweeted
Alligator Bioscience receives government research grant bit.se/wNUOTe
Peter Ellmark retweeted
Don't miss out @AlligatorBio Head of Discovery Peter Ellmark today in Aftonbladet Morning TV, giving his reflections on this year's Nobel Prize in medicine and the immunotherapy field. tv.aftonbladet.se/abtv/artic… #immunotherapy #endcancer #arevolutionforlife
Peter Ellmark retweeted
Congratulations to Dr. Jim Allison on winning the 2018 #NobelPrize in Medicine for his groundbreaking work in #immunotherapy #CTLA4. Alligator Bioscience's bispecific ATOR-1015 is designed to bring CTLA-4 therapy to the next level. #endcancer #arevolutionforlife
Peter Ellmark retweeted
New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017 bit.se/u8VJzk
Peter Ellmark retweeted
A room filled to the last chair. CEO Per Norlén on stage @Redeye_ Investor After Work at Clarion Hotel Malmö Live #immunooncology #arevolutionforlife
Peter Ellmark retweeted
Today Dr Peter Ellmark, Alligator Vice President Discovery, gives a talk about drug discovery at the event Academic Drug Discovery – how to secure that preclinical findings reach the patients, in Copenhagen. mva.org/event/academic-drug-… #immunooncology #arevolutionforlife
Peter Ellmark retweeted
Att se homeopati som ett ofarligt komplement till evidensbaserad medicin är som att se lögnen som ett ofarligt komplement till sanningen. independent.co.uk/news/healt…
Peter Ellmark retweeted
#JITC Commentary: A team effort: natural killer cells on the first leg of the tumor immunity relay race ow.ly/5nIe30kRFTk




















